RedHill's phase 2/3 COVID-19 study of opaganib passes second DSMB review
Credit: RedHill Biopharma -- Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021 -- Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib -- Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involved in viral replication TEL AVIV, Israel and RALEIGH, NC, December 22, 2020, ...
Source: eurekalert.org